Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACeS anticoagulation for new-onset postoperative atrial fibrillation after CABG
2024-515924-35-00Phase 4Authorised
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2023
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban, apixaban, edoxaban, dabigatran, phenprocoumon and 3 more in Atrial fibrillation (AFib) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Primary effectiveness endpoint and Primary safety endpoint. Planned start Jan 2023; status: authorised.
02
Drugs
rivaroxabanapixabanedoxabandabigatranphenprocoumon
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2024-515924-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515924-35-00.